Pitavastatin Shows Promise in Preventing Cardiovascular Disease in People with HIV
Recent research indicates that pitavastatin, a statin medication, may significantly reduce the risk of cardiovascular events in individuals living with HIV. This finding is particularly important given the increased burden of cardiovascular disease (CVD) among people with HIV (PLWH).
The Growing Cardiovascular Risk for People with HIV
For decades, the global incidence of cardiovascular disease among people living with HIV has been on the rise. This increased risk is likely multifactorial, stemming from a combination of factors including HIV itself, inflammation associated with the virus, and potential side effects of antiretroviral therapy (ART) . Some ART medications are believed to have heart-related side effects, further complicating the issue .
REPRIEVE Trial Results
The REPRIEVE trial, the largest randomized trial to date focusing on HIV and cardiovascular health, demonstrated a 36% reduction in the incidence of heart disease events among participants who took pitavastatin calcium . These results have been incorporated into clinical guidelines, with the Department of Health and Human Services releasing recommendations for statin therapy in PLWH in February 2024 .
Pitavastatin and the NEJM Study
A study published in the New England Journal of Medicine in July 2023 further supports the benefits of pitavastatin. Participants with HIV who received pitavastatin experienced a lower risk of major adverse cardiovascular events compared to those who received a placebo .
Study Participant Characteristics
The participants in these trials often present with complexities beyond HIV. The average age of participants was 60, older than those typically included in HIV drug trials. Many were taking multiple medications to manage HIV, with a regimen ranging from two to eleven pills daily. A significant proportion similarly had pre-existing conditions like cardiovascular or kidney disease, and a history of resistance to previous antiretroviral therapies.
Additional Benefits Observed
Interestingly, participants in the pitavastatin groups often experienced fewer side effects, such as increased cholesterol levels, suggesting a potential added benefit for those already at risk for heart disease. The medication’s ease of use and convenience may also improve adherence to daily therapy, which is crucial for older adults and individuals with complex treatment histories.
Looking Ahead
The growing body of evidence supporting pitavastatin’s role in preventing cardiovascular disease in PLWH is paving the way for updated clinical guidelines and improved patient care. Continued research and monitoring will be essential to optimize treatment strategies and further reduce the risk of CVD in this vulnerable population.